Cumberland Pharmaceuticals Inc (CPIX) Unusual Options Activity Today

Checking CPIX unusual options activity helps you spot when traders are making outsized bets on Cumberland Pharmaceuticals Inc before the broader market catches on. Cumberland Pharmaceuticals Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor CPIX unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching CPIX unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking CPIX unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and CPIX unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Catalysts rarely arrive without a footprint, and CPIX unusual options activity is often where that footprint shows up first. Our scanner tracks Cumberland Pharmaceuticals Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at CPIX unusual options volume on the call side or chasing put sweeps, Cumberland Pharmaceuticals Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.